Search

Your search keyword '"Paillot, B."' showing total 28 results
Start Over Author "Paillot, B." Search Limiters Peer Reviewed
28 results on '"Paillot, B."'

1. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Adenis, A., Alessio, A., Aouakli, A., Azzedine, A., Bedjaoui, A., Bidault, A., Blanchi, A., Botton, A., Cadier-Lagnes, A., Fatisse, A., Gagnaire, A., Gilbert, A., Gueye, A., Hollebecque, A., Lemaire, A., Mahamat, A., Marre, A., Patenotte, A., Rotenberg, A., Roussel, A., Thirot-Bidault, A., Votte, A., Weber, A., Zaanan, A., Dupont-Gossart, A.C., Villing, A.L., Queuniet, A.M., Coudert, B., Denis, B., Garcia, B., Lafforgue, B., Landi, B., Leduc, B., Linot, B., Paillot, B., Rhein, B., Winkfield, B., Barberis, C., Becht, C., Belletier, C., Berger, C., Bineau, C., Borel, C., Brezault, C., Buffet, C., Cornila, C., Couffon, C., De La Fouchardière, C., Giraud, C., Lecaille, C., Lepere, C., Lobry, C., Locher, C., Lombard-Bohas, C., Paoletti, C., Platini, C., Rebischung, C., Sarda, C., Vilain, C., Briac-Levaché, C., Auby, D., Baudet-Klepping, D., Bechade, D., Besson, D., Cleau, D., Festin, D., Gargot, D., Genet, D., Goldfain, D., Luet, D., Malka, D., Peré-Vergé, D., Pillon, D., Sevin-Robiche, D., Smith, D., Soubrane, D., Tougeron, D., Zylberait, D., Carola, E., Cuillerier, E., Dorval Danquechin, E., Echinard, E., Janssen, E., Maillard, E., Mitry, E., Norguet-Monnereau, E., Suc, E., Terrebonne, E., Zrihen, E., Pariente, E.A., Almaric, F., Audemar, F., Bonnetain, F., Desseigne, F., Dewaele, F., Di Fiore, F., Ghiringhelli, F., Husseini, F., Khemissa, F., Kikolski, F., Morvan, F., Petit-Laurent, F., Riot, F., Subtil, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Bordes, G., Cavaglione, G., Coulanjon, G., Deplanque, G., Gatineau-Saillant, G., Goujon, G., Medinger, G., Roquin, G., Brixi-Benmansour, H., Castanie, H., Lacroix, H., Maechel, H., Perrier, H., Salloum, H., Senellart, H., Baumgaertner, I., Cumin, I., Graber, I., Trouilloud, I., Boutin, J., Butel, J., Charneau, J., Cretin, J., Dauba, J., Deguiral, J., Egreteau, J., Ezenfis, J., Forestier, J., Goineau, J., Lacourt, J., Lafon, J., Martin, J., Meunier, J., Moreau, J., Provencal, J., Taieb, J., Thaury, J., Tuaillon, J., Vergniol, J., Villand, J., Vincent, J., Volet, J., Bachet, J.B., Barbare, J.C., Souquet, J.C., Grangé, J.D., Dor, J.F., Paitel, J.F., Jouve, J.L., Raoul, J.L., Cheula, J.M., Gornet, J.M., Sabate, J.M., Vantelon, J.M., Vaillant, J.N., Aucouturier, J.P., Barbieux, J.P., Herr, J.P., Lafargue, J.P., Lagasse, J.P., Latrive, J.P., Plachot, J.P., Ramain, J.P., Robin, J.P., Spano, J.P., Douillard, J.Y., Beerblock, K., Bouhier-Leporrier, K., Slimane Fawzi, K., Cany, L., Chone, L., Dahan, L., Gasnault, L., Rob, L., Stefani, L., Wander, L., Baconnier, M., Ben Abdelghani, M., Benchalal, M., Blasquez, M., Carreiro, M., Charbit, M., Combe, M., Duluc, M., Fayolle, M., Gignoux, M., Giovannini, M., Glikmanas, M., Mabro, M., Mignot, M., Mornet, M., Mousseau, M., Mozer, M., Pauwels, M., Pelletier, M., Porneuf, M., Ramdani, M., Schnee, M., Tissot, M., Zawadi, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Galais, M.P., Abdelli, N., Barrière, N., Bouaria, N., Bouarioua, N., Delas, N., Gérardin, N., Hess-Laurens, N., Stremsdoerfer, N., Berthelet, O., Boulat, O., Capitain, O., Favre, O., Amoyal, P., Bergerault, P., Burtin, P., Cassan, P., Chatrenet, P., Chiappa, P., Claudé, P., Couzigou, P., Feydy, P., Follana, P., Geoffroy, P., Godeau, P., Hammel, P., Laplaige, P., Lehair, P., Martin, P., Novello, P., Pantioni, P., Pienkowski, P., Pouderoux, P., Prost, P., Ruszniewski, P., Souillac, P., Texereau, P., Thévenet, P., Haineaux, P.A., Benoit, R., Coriat, R., Lamy, R., Mackiewicz, R., Beorchia, S., Chaussade, S., Hiret, S., Jacquot, S., Lavau Denes, S., Montembault, S., Nahon, S., Nasca, S., Nguyen, S., Oddou-Lagraniere, S., Pesque-Penaud, S., Fratte, S.P., Chatellier, T., Mansourbakht, T., Morin, T., Walter, T., Boige, V., Bourgeois, V., Derias, V., Guérin-Meyer, V., Hautefeuille, V., Jestin Le Tallec, V., Lorgis, V., Quentin, V., Sebbagh, V., Veuillez, V., Adhoute, X., Coulaud, X., Becouarn, Y., Coscas, Y., Courouble, Y., Le Bricquir, Y., Molin, Y., Rinaldi, Y., Lam, Y.H., Ladhib, Z., Aparicio, Thomas, Ducreux, Michel, Faroux, Roger, Barbier, Emilie, Manfredi, Sylvain, Lecomte, Thierry, Etienne, Pierre-Luc, Bedenne, Laurent, Bennouna, Jaafar, Phelip, Jean-Marc, François, Eric, Michel, Pierre, Legoux, Jean-Louis, Gasmi, Mohamed, Breysacher, Gilles, Rougier, Philippe, De Gramont, Aimery, Lepage, Come, Bouché, Olivier, and Seitz, Jean-François

Published
2018
Full Text
View/download PDF

2. Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn′s Disease: A French Population-Based Study

Author

Duricova, Dana, Sarter, Hélène, Savoye, Guillaume, Leroyer, Ariane, Pariente, Benjamin, Armengol-Debeir, Laura, Bouguen, Guillaume, Ley, Delphine, Turck, Dominique, Templier, Carole, Buche, Sebastien, Peyrin-Biroulet, Laurent, Gower-Rousseau, Corinne, Fumery, Mathurin, Andre, J M, Antonietti, M, Aouakli, A, Armand, A, Aroichane, I, Assi, F, Aubet, J P, Auxenfants, E, Ayafi-Ramelot, F, Bankovski, D, Barbry, B, Bardoux, N, Baron, P, Baudet, A, Bazin, B, Bebahani, A, Becqwort, J P, Benet, V, Benali, H, Benguigui, C, Ben Soussan, E, Bental, A, Berkelmans, I, Bernet, J, Bernou, K, Bernou-Dron, C, Bertot, P, Bertiaux-Vandaële, N, Bertrand, V, Billoud, E, Biron, N, Bismuth, B, Bleuet, M, Blondel, F, Blondin, V, Bohon, P, Boniface, E, Bonnière, P, Bonvarlet, E, Bonvarlet, P, Boruchowicz, A, Bostvironnois, R, Boualit, M, Bouche, B, Boudaillez, C, Bourgeaux, C, Bourgeois, M, Bourguet, A, Bourienne, A, Branche, J, Bray, G, Brazier, F, Breban, P, Brihier, H, Brung-Lefebvre, V, Bulois, P, Burgiere, P, Butel, J, Canva, J Y, Canva-Delcambre, V, Capron, J P, Cardot, F, Carpentier, P, Cartier, E, Cassar, J F, Cassagnou, M, Castex, J F, Catala, P, Cattan, S, Catteau, S, Caujolle, B, Cayron, G, Chandelier, C, Chantre, M, Charles, J, Charneau, T, Chavance-Thelu, M, Chirita, D, Choteau, A, Claerbout, J F, Clergue, P Y, Coevoet, H, Cohen, G, Collet, R, Colombel, J F, Coopman, S, Corvisart, J, Cortot, A, Couttenier, F, Crinquette, J F, Crombe, V, Dadamessi, I, Dapvril, V, Davion, T, Dautreme, S, Debas, J, Degrave, N, Dehont, F, Delatre, C, Delcenserie, R, Delette, O, Delgrange, T, Delhoustal, L, Delmotte, J S, Demmane, S, Deregnaucourt, G, Descombes, P, Desechalliers, J P, Desmet, P, Desreumaux, P, Desseaux, G, Desurmont, P, Devienne, A, Devouge, E, Devred, M, Devroux, A, Dewailly, A, Dharancy, S, Di Fiore, A, Djeddi, D, Djedir, R, Dreher-Duwat, M L, Dubois, R, Dubuque, C, Ducatillon, P, Duclay, J, Ducrocq, B, Ducrot, F, Ducrotté, P, Dufilho, A, Duhamel, C, Dujardin, D, Dumant-Forest, C, Dupas, J L, Dupont, F, Duranton, Y, Duriez, A, El Achkar, K, El Farisi, M, Elie, C, Elie-Legrand, M C, Elkhaki, A, Eoche, M, Evrard, D, Evrard, J P, Fatome, A, Filoche, B, Finet, L, Flahaut, M, Flamme, C, Foissey, D, Fournier, P, Foutrein- Comes, M C, Foutrein, P, Fremond, D, Frere, T, Fumery, M, Gallet, P, Gamblin, C, Ganga-Zandzou, S, Gerard, R, Geslin, G, Gheyssens, Y, Ghossini, N, Ghrib, S, Gilbert, T, Gillet, B, Godard, D, Godard, P, Godchaux, J M, Godchaux, R, Goegebeur, G, Goria, O, Gottrand, F, Gower, P, Grandmaison, B, Groux, M, Guedon, C, Guillard, J F, Guillem, L, Guillemot, F, Guimber, D, Haddouche, B, Hakim, S, Hanon, D, Hautefeuille, V, Heckestweiller, P, Hecquet, G, Hedde, J P, Hellal, H, Henneresse, P E, Heyman, B, Heraud, M, Herve, S, Hochain, P, Houssin-Bailly, L, Houcke, P, Huguenin, B, Iobagiu, S, Ivanovic, A, Iwanicki-Caron, I, Janicki, E, Jarry, M, Jeu, J, Joly, J P, Jonas, C, Katherin, F, Kerleveo, A, Khachfe, A, Kiriakos, A, Kiriakos, J, Klein, O, Kohut, M, Kornhauser, R, Koutsomanis, D, Laberenne, J E, Laffineur, G, Lagarde, M, Lannoy, P, Lapchin, J, Lapprand, M, Laude, D, Leblanc, R, Lecieux, P, Leclerc, N, Le Couteulx, C, Ledent, J, Lefebvre, J, Lefiliatre, P, Legrand, C, Le Grix, A, Lelong, P, Leluyer, B, Lenaerts, C, Lepileur, L, Leplat, A, Lepoutre-Dujardin, E, Leroi, H, Leroy, M Y, Lesage, J P, Lesage, X, Lesage, J, Lescanne-Darchis, I, Lescut, J, Lescut, D, Leurent, B, Levy, P, Lhermie, M, Lion, A, Lisambert, B, Loire, F, Louf, S, Louvet, A, Luciani, M, Lucidarme, D, Lugand, J, Macaigne, O, Maetz, D, Maillard, D, Mancheron, H, Manolache, O, Marks-Brunel, A B, Marti, R, Martin, F, Martin, G, Marzloff, E, Mathurin, P, Mauillon, J, Maunoury, V, Maupas, J L, Mesnard, B, Metayer, P, Methari, L, Meurisse, B, Meurisse, F, Michaud, L, Mirmaran, X, Modaine, P, Monthe, A, Morel, L, Mortier, P E, Moulin, E, Mouterde, O, Mudry, J, Nachury, M, N’Guyen Khac, E, Notteghem, B, Ollevier, V, Ostyn, A, Ouraghi, A, Ouvry, D, Paillot, B, Panien-Claudot, N, Paoletti, C, Papazian, A, Parent, B, Pariente, B, Paris, J C, Patrier, P, Paupart, L, Pauwels, B, Pauwels, M, Petit, R, Piat, M, Piotte, S, Plane, C, Plouvier, B, Pollet, E, Pommelet, P, Pop, D, Pordes, C, Pouchain, G, Prades, P, Prevost, A, Prevost, J C, Quesnel, B, Queuniet, A M, Quinton, J F, Rabache, A, Rabelle, P, Raclot, G, Ratajczyk, S, Rault, D, Razemon, V, Reix, N, Revillon, M, Richez, C, Robinson, P, Rodriguez, J, Roger, J, Roux, J M, Rudelli, A, Saber, A, Savoye, G, Schlosseberg, P, Segrestin, M, Seguy, D, Serin, M, Seryer, A, Sevenet, F, Shekh, N, Silvie, J, Simon, V, Spyckerelle, C, Talbodec, N, Techy, A, Thelu, J L, Thevenin, A, Thiebault, H, Thomas, J, Thorel, J M, Tielman, G, Tode, M, Toisin, J, Tonnel, J, Touchais, J Y, Touze, Y, Tranvouez, J L, Triplet, C, Turck, D, Uhlen, S, Vaillant, E, Valmage, C, Vanco, D, Vandamme, H, Vanderbecq, E, Vander Eecken, E, Vandermolen, P, Vandevenne, P, Vandeville, L, Vandewalle, A, Vandewalle, C, Vaneslander, P, Vanhoove, J P, Vanrenterghem, A, Varlet, P, Vasies, I, Verbiese, G, Vernier-Massouille, G, Vermelle, P, Verne, C, Vezilier-Cocq, P, Vigneron, B, Vincendet, M, Viot, J, Voiment, Y M, Wacrenier, A, Waeghemaecker, L, Wallez, J Y, Wantiez, M, Wartel, F, Weber, J, Willocquet, J L, Wizla, N, Wolschies, E, Zalar, A, Zaouri, B, Zellweger, A, and Ziade, C

Published
2019
Full Text
View/download PDF

3. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study

Author

Hochart, A, Gower-Rousseau, C, Sarter, H, Fumery, M, Ley, D, Spyckerelle, C, Peyrin-Biroulet, L, Laberenne, J-E, Vasseur, F, Savoye, G, Turck, D, Andre, JM, Antonietti, M, Aouakli, A, Armand, A, Aroichane, I, Assi, F, Aubet, JP, Auxenfants, E, Ayafi-Ramelot, F, Azzouzi, K, Bankovski, D, Barbry, B, Bardoux, N, Baron, P, Baudet, A, Bazin, B, Bebahani, A, Becqwort, JP, Benet, V, Benali, H, Benguigui, C, Ben Soussan, E, Bental, A, Berkelmans, I, Bernet, J, Bernou, K, Bernou-Dron, C, Bertot, P, Bertiaux-Vandaële, N, Bertrand, V, Billoud, E, Biron, N, Bismuth, B, Bleuet, M, Blondel, F, Blondin, V, Bohon, P, Boniface, E, Bonnière, P, Bonvarlet, E, Bonvarlet, P, Boruchowicz, A, Bostvironnois, R, Boualit, M, Bouche, B, Boudaillez, C, Bourgeaux, C, Bourgeois, M, Bourguet, A, Bourienne, A, Branche, J, Bray, G, Brazier, F, Breban, P, Bridenne, M, Brihier, H, Brung-Lefebvre, V, Bulois, P, Burgiere, P, Butel, J, Canva, JY, Canva-Delcambre, V, Capron, JP, Cardot, F, Carpentier, P, Cartier, E, Cassar, JF, Cassagnou, M, Castex, JF, Catala, P, Cattan, S, Catteau, S, Caujolle, B, Cayron, G, Chandelier, C, Chantre, M, Charles, J, Charneau, T, Chavance-Thelu, M, Chirita, D, Choteau, A, Claerbout, JF, Clergue, PY, Coevoet, H, Cohen, G, Collet, R, Colombel, JF, Coopman, S, Corvisart, J, Cortot, A, Couttenier, F, Crinquette, JF, Crombe, V, Dadamessi, I, Dapvril, V, Davion, T, Dautreme, S, Debas, J, Degrave, N, Dehont, F, Delatre, C, Delcenserie, R, Delette, O, Delgrange, T, Delhoustal, L, Delmotte, JS, Demmane, S, Deregnaucourt, G, Descombes, P, Desechalliers, JP, Desmet, P, Desreumaux, P, Desseaux, G, Desurmont, P, Devienne, A, Devouge, E, Devred, M, Devroux, A, Dewailly, A, Dharancy, S, Di Fiore, A, Djeddi, D, Djedir, R, Dreher-Duwat, ML, Dubois, R, Dubuque, C, Ducatillon, P, Duclay, J, Ducrocq, B, Ducrot, F, Ducrotte, P, Dufilho, A, Duhamel, C, Dujardin, D, Dumant-Forest, C, Dupas, JL, Dupont, F, Duranton, Y, Duriez, A, El Achkar, K, El Farisi, M, Elie, C, Elie-Legrand, MC, Elkhaki, A, Eoche, M, Evrard, D, Evrard, JP, Fatome, A, Filoche, B, Finet, L, Flahaut, M, Flamme, C, Foissey, D, Fournier, P, Foutrein-Comes, MC, Foutrein, P, Fremond, D, Frere, T, Gallet, P, Gamblin, C, Ganga, S, Gerard, R, Geslin, G, Gheyssens, Y, Ghossini, N, Ghrib, S, Gilbert, T, Gillet, B, Godard, D, Godard, P, Godchaux, JM, Godchaux, R, Goegebeur, G, Goria, O, Gottrand, F, Gower, P, Grandmaison, B, Groux, M, Guedon, C, Guillard, JF, Guillem, L, Guillemot, F, Guimberd, D, Haddouche, B, Hakim, S, Hanon, D, Hautefeuille, V, Heckestweiller, P, Hecquet, G, Hedde, JP, Hellal, H, Henneresse, PE, Heyman, B, Heraud, M, Herve, S, Hochain, P, Houssin-Bailly, L, Houcke, P, Huguenin, B, Iobagiu, S, Ivanovic, A, Iwanicki-Caron, I, Janicki, E, Jarry, M, Jeu, J, Joly, JP, Jonas, C, Katherin, F, Kerleveo, A, Khachfe, A, Kiriakos, A, Kiriakos, J, Klein, O, Kohut, M, Kornhauser, R, Koutsomanis, D, Laffineur, G, Lagarde, M, Lalanne, A, Lannoy, P, Lapchin, J, Laprand, M, Laude, D, Leblanc, R, Lecieux, P, Leclerc, N, Le Couteulx, C, Ledent, J, Lefebvre, J, Lefiliatre, P, Legrand, C, Le Grix, A, Lelong, P, Leluyer, B, Lenaerts, C, Lepileur, L, Leplat, A, Lepoutre-Dujardin, E, Leroi, H, Leroy, MY, Lesage, JP, Lesage, X, Lesage, J, Lescanne-Darchis, I, Lescut, J, Lescut, D, Leurent, B, Levy, P, Lhermie, M, Lion, A, Lisambert, B, Loire, F, Louf, S, Louvet, A, Luciani, M, Lucidarme, D, Lugand, J, Macaigne, O, Maetz, D, Maillard, D, Mancheron, H, Manolache, O, Marks-Brunel, AB, Marti, R, Martin, F, Martin, G, Marzloff, E, Mathurin, P, Mauillon, J, Maunoury, V, Maupas, JL, Mesnard, B, Metayer, P, Methari, L, Meurisse, B, Meurisse, F, Michaud, L, Mirmaran, X, Modaine, P, Monthe, A, Morel, L, Mortier, PE, Moulin, E, Mouterde, O, Mudry, J, Nachury, M, NʼGuyen Khac, E, Notteghem, B, Ollevier, V, Ostyn, A, Ouraghi, A, Ouvry, D, Paillot, B, Panien-Claudot, N, Paoletti, C, Papazian, A, Parent, B, Pariente, B, Paris, JC, Patrier, P, Paupart, L, Pauwels, B, Pauwels, M, Petit, R, Piat, M, Piotte, S, Plane, C, Plouvier, B, Pollet, E, Pommelet, P, Pop, D, Pordes, C, Pouchain, G, Prades, P, Prevost, A, Prevost, JC, Quesnel, B, Queuniet, AM, Quinton, JF, Rabache, A, Rabelle, P, Raclot, G, Ratajczyk, S, Rault, D, Razemon, V, Reix, N, Revillon, M, Richez, C, Robinson, P, Rodriguez, J, Roger, J, Roux, JM, Rudelli, A, Saber, A, Schlosseberg, P, Segrestin, M, Seguy, D, Serin, M, Seryer, A, Sevenet, F, Shekh, N, Silvie, J, Simon, V, Talbodec, N, Techy, A, Thelu, JL, Thevenin, A, Thiebault, H, Thomas, J, Thorel, JM, Tielman, G, Tode, M, Toisin, J, Tonnel, J, Touchais, JY, Touze, Y, Tranvouez, JL, Triplet, C, Uhlen, S, Vaillant, E, Valmage, C, Vanco, D, Vandamme, H, Vanderbecq, E, Vander Eecken, E, Vandermolen, P, Vandevenne, P, Vandeville, L, Vandewalle, A, Vandewalle, C, Vaneslander, P, Vanhoove, JP, Vanrenterghem, A, Varlet, P, Vasies, I, Verbiese, G, Vernier-Massouille, G, Vermelle, P, Verne, C, Vezilier-Cocq, P, Vigneron, B, Vincendet, M, Viot, J, Voiment, YM, Wacrenier, A, Waeghemaecker, L, Wallez, JY, Wantiez, M, Wartel, F, Weber, J, Willocquet, JL, Wizla, N, Wolschies, E, Zalar, A, Zaouri, B, Zellweger, A, and Ziade, C

Published
2017
Full Text
View/download PDF

4. Chemoprevention of metachronous adenomas of the large bowel: design and interim results of a randomized trial of calcium and fibre

Author

the ECP Colon Group, Faivre, J, Couillault, C, Kronborg, O, Rath, U, Giacosa, A, De Oliveira, H, Obrador, T, O'Morain, C, Andreatta, R, Buset, M, Crespon, B, Fenger, K, Justum, A M, Kerr, G, Legoux, J L, Marks, C, Matek, W, Owen, R W, Paillot, B, Piard, F, Pienkowski, P, Pignatelle, M, Prada, A, Pujol, J, Rozen, P, Richter, F, Seitz, J F, Sturniolo, G C, and Zambelli, A

Published
1997

14. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Author

Nordlinger, B, Sorbye, H, Glimelius, B, Poston, Gj, Schlag, Pm, Rougier, P, Bechstein, Wo, Primrose, Jn, Walpole, Et, FINCH JONES, M, Jaeck, D, Mirza, D, Parks, Rw, Collette, L, Praet, M, Bethe, U, VAN CUTSEM, E, Scheithauer, W, Gruenberger, T, Hohenberger, W, Iveson, T, Karner, J, Levi, J, Hugh, T, DE GREVE, J, Chan, A, Davidson, B, Lindner, P, Peeters, M, Stein, B, Diamond, T, Ducreux, M, Lasser, P, Graeven, U, Paillot, B, Doran, J, Gouillat, C, Iesalnieks, I, Jauch, Kw, JAGOT LACOUSSIERE, P, Jansen, Rl, Koehne, H, Konopke, R, Otto, F, Sherlock, D, VAN HAZEL, G, Ackland, S, Bedenne, L, Bories, E, CLAVERO FABRI MC, Conroy, T, KAMINSKY FORRETT MC, Husseini, F, Karapetis, C, Mãœller, L, Price, T, Rosenberg, R, Schott, J, Tschmelitsch, J, VAN LAETHEM JL, Wals, J, Weimann, A, Arnaud, Jp, Arsene, D, Auby, D, Bhattacharya, S, Cebon, E, Cherqui, D, Confente, C, Dousset, B, Frickhofen, N, Frilling, A, Evan, P, Ganju, V, Hã–ffken, K, Lazorthes, F, Letoublon, C, Madroszyk, A, Nitti, Donato, Orr, B, Pariente, Ea, Pector, Jc, Raoul, Jl, Rees, M, Ridwelski, K, Rouanet, P, Toogood, Gj, Vergauwe, P, Wilke, Hj, Kaplan, R, Horiot, Jc, Littbrand, B, Awada, A, Stenning, S, Lejeune, F., Haukeland University Hospital, University of Bergen (UiB), Uppsala Universitet [Uppsala], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre de Chirurgie Viscérale, Hépatique et de Transplantation Multiorganes, Université Louis Pasteur - Strasbourg I, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), University Hospitals Leuven [Leuven], Centre Énergétique et Procédés (CEP), MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), and Université d'Angers (UA)

Subjects
Adult, Male, medicine.medical_specialty, Organoplatinum Compounds, Colorectal cancer, [SDV]Life Sciences [q-bio], 030230 surgery, Perioperative Care, 03 medical and health sciences, 0302 clinical medicine, Hepatic arterial infusion, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, business.industry, Liver Neoplasms, Hazard ratio, Cancer, General Medicine, Perioperative, Middle Aged, medicine.disease, Combined Modality Therapy, 3. Good health, Surgery, Oxaliplatin, Clinical trial, 030220 oncology & carcinogenesis, Female, Fluorouracil, Colorectal Neoplasms, Liver cancer, business, medicine.drug
Abstract

Summary Background Surgical resection alone is regarded as the standard of care for patients with liver metastases from colorectal cancer, but relapse is common. We assessed the combination of perioperative chemotherapy and surgery compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Methods This parallel-group study reports the trial's final data for progression-free survival for a protocol unspecified interim time-point, while overall survival is still being monitored. 364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group). Patients were centrally randomised by minimisation, adjusting for centre and risk score. The primary objective was to detect a hazard ratio (HR) of 0·71 or less for progression-free survival. Primary analysis was by intention to treat. Analyses were repeated for all eligible (171 vs 171) and resected patients (151 vs 152). This trial is registered with ClinicalTrials.gov, number NCT00006479. Findings In the perioperative chemotherapy group, 151 (83%) patients were resected after a median of six (range 1–6) preoperative cycles and 115 (63%) patients received a median six (1–8) postoperative cycles. 152 (84%) patients were resected in the surgery group. The absolute increase in rate of progression-free survival at 3 years was 7·3% (from 28·1% [95·66% CI 21·3–35·5] to 35·4% [28·1–42·7]; HR 0·79 [0·62–1·02]; p=0·058) in randomised patients; 8·1% (from 28·1% [21·2–36·6] to 36·2% [28·7–43·8]; HR 0·77 [0·60–1·00]; p=0·041) in eligible patients; and 9·2% (from 33·2% [25·3–41·2] to 42·4% [34·0–50·5]; HR 0·73 [0·55–0·97]; p=0·025) in patients undergoing resection. 139 patients died (64 in perioperative chemotherapy group vs 75 in surgery group). Reversible postoperative complications occurred more often after chemotherapy than after surgery (40/159 [25%] vs 27/170 [16%]; p=0·04). After surgery we recorded two deaths in the surgery alone group and one in the perioperative chemotherapy group. Interpretation Perioperative chemotherapy with FOLFOX4 is compatible with major liver surgery and reduces the risk of events of progression-free survival in eligible and resected patients. Funding Swedish Cancer Society, Cancer Research UK, Ligue Nationale Contre le Cancer, US National Cancer Institute, Sanofi-Aventis.

Published
2008
Full Text
View/download PDF

16. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer.

Author

Tougeron, D, Di Fiore, F, Thureau, S, Berbera, N, Iwanicki-Caron, I, Hamidou, H, Paillot, B, and Michel, P

Subjects
TREATMENT of esophageal cancer, RADIOTHERAPY, OLDER patients, CISPLATIN, TOMOGRAPHY, CANCER patients
Abstract

Little is known about chemoradiotherapy (CRT) in elderly patients with a locally advanced oesophageal cancer (OC). The aim of our study was to evaluate the tolerance and the outcome of elderly patients older than 70 years treated with CRT for a non-metastatic OC. Chemoradiotherapy was based on radiotherapy combined with a cisplatin-based chemotherapy. Clinical complete response (CCR) to CRT was evaluated on upper digestive endoscopy and computed tomography scan 6-8 weeks after CRT completion. One hundred and nine consecutive patients were included. A CCR was observed in 63 patients (57.8%) and 2-year survival was 35.5%. Adverse events > or =grade 3 were observed in 26 (23.8%) patients. Chemotherapy dose reduction, chemotherapy delays more than 1 week, and treatment discontinuation were observed in 33 (30.3%), 45 (41.3%), and 17 patients (15.6%), respectively. Comorbidity index according to Charlson score was significantly associated with treatment tolerance. In multivariate analysis, a CCR to CRT (P<0.01), a dose of radiotherapy > or =80% (P=0.02), and a Charlson score < or =2 (P=0.046) were identified as independent prognostic factors of overall survival. These results suggest that CRT could be considered as an effective treatment without major toxicity in elderly patients with OC. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

18. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

Author

Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., Queuniet, A. M., Paillot, B., Sabourin, J. C., Michot, F., Michel, P., and Frebourg, T.

Subjects
COLON cancer, GENETIC mutation, CETUXIMAB, DRUG therapy, MEDICAL screening, CANCER patients
Abstract

The predictive value of KRAS mutation in metastatic colorectal cancer (MCRC) patients treated with cetuximab plus chemotherapy has recently been suggested. In our study, 59 patients with a chemotherapy-refractory MCRC treated with cetuximab plus chemotherapy were included and clinical response was evaluated according to response evaluation criteria in solid tumours (RECIST). Tumours were screened for KRAS mutations using first direct sequencing, then two sensitive methods based on SNaPshot and PCR-ligase chain reaction (LCR) assays. Clinical response was evaluated according to gene mutations using the Fisher exact test. Times to progression (TTP) were calculated using the Kaplan–Meier method and compared with log-rank test. A KRAS mutation was detected in 22 out of 59 tumours and, in six cases, was missed by sequencing analysis but detected using the SNaPshot and PCR-LCR assays. Remarkably, no KRAS mutation was found in the 12 patients with clinical response. KRAS mutation was associated with disease progression (P=0.0005) and TTP was significantly decreased in mutated KRAS patients (3 vs 5.5 months, P=0.015). Our study confirms that KRAS mutation is highly predictive of a non-response to cetuximab plus chemotherapy in MCRC and highlights the need to use sensitive molecular methods, such as SNaPshot or PCR-LCR assays, to ensure an efficient mutation detection.British Journal of Cancer (2007) 96, 1166–1169. doi:10.1038/sj.bjc.6603685 www.bjcancer.com Published online 20 March 2007 [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

20. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.

Author

Michel, P., Adenis, A., Di Fiore, F., Boucher, E., Galais, M. P., Dahan, L., Mirabel, X., Hamidou, H., Raoul, J. L., Jacob, J. H., Hellot, M. F., Prod'Homme, S., and Paillot, B.

Subjects
ESOPHAGUS diseases, CANCER radiotherapy, CANCER chemotherapy, CISPLATIN, ANTINEOPLASTIC agents, MEDICAL research, THERAPEUTIC use of antineoplastic agents, SURVIVAL, RESEARCH, CLINICAL trials, RESEARCH methodology, CAMPTOTHECIN, DEGLUTITION disorders, EVALUATION research, TREATMENT effectiveness, TUMOR classification, COMPARATIVE studies, RADIATION doses, COMBINED modality therapy, ESOPHAGEAL tumors, SQUAMOUS cell carcinoma, DISEASE remission
Abstract

A recent phase I study showed that weekly cisplatin, irinotecan and concurrent radiotherapy can be administered with moderate toxicity in patients with oesophageal cancer. Patients with no prior treatment and oesophageal cancer stage I to III, performance status <3, caloric intake >1,500 kcal day(-1) were included. Chemotherapy, with cisplatin 30 mg m(-2) and irinotecan 60 mg m(-2), was administered at days 1, 8, 22, 29, and concurrently with radiotherapy at days 43, 50, 64 and 71. Radiotherapy was delivered with 50 or 50.4 Gy in 25 fractions/5 weeks. Forty-three patients were included, 10 stage I, 19 stage II and 14 stage III. Mean age was 59.2 years (range 44-79). A total of 30 out of 43 (69.8%) patients underwent all planned treatment. During induction chemotherapy, 14 severe toxicities of grade 3 or 4 in 10 patients (23.3%) were reported with 57.1% due to haematoxicity. During chemoradiotherapy, 31 severe toxicities of grade 3 or 4 with 64.5% due to haematotoxicity were reported in 18 patients. One toxic death occurred (diarrhoea grade 4). The complete clinical response rate was 58.1% (95% CI: 43.4-72.8%). Overall survival rate at 1 and 2 years was 62.8%, (95% CI, 58.3-77.3%) and 27.9% (95% CI, 13.4-41.3%), respectively. In conclusion, cisplatin-irinotecan-radiotherapy is an active and well-tolerated regimen feasible in out-patients. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

21. 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.

Author

Bennouna, J., Perrier, H., Paillot, B., Priou, F., Jacob, J. H., Hebbar, M., Bordenave, S., Seitz, J. F., Cvitkovic, F., Dorval, E., Malek, K., Tonelli, D., and Douillard, J. Y.

Subjects
URACIL, FOLINIC acid, PATIENTS, NEUTROPENIA, NEUROPATHY, ANTINEOPLASTIC agents, THERAPEUTIC use of antineoplastic agents, RESEARCH, INTRAVENOUS therapy, DIARRHEA, CLINICAL trials, HETEROCYCLIC compounds, ORAL drug administration, RESEARCH methodology, METASTASIS, PERIPHERAL nervous system, MEDICAL cooperation, EVALUATION research, COLORECTAL cancer, ORGANOPLATINUM compounds, TREATMENT effectiveness, FLUOROURACIL, COMPARATIVE studies, SURVIVAL analysis (Biometry)
Abstract

This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT®)/leucovorin (LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for metastatic disease. Between February 2002 and October 2002, 64 patients received UFT® 300 mg m-2 day-1 and LV 90 mg day-1 from day 1 to day 14 combined with oxaliplatin 130 mg m-2 on day 1, every 3 weeks. All patients were evaluable for safety analysis and 58 of 64 patients were eligible for efficacy. Responses were reviewed by an independent review committee. Of the 58 perprotocol defined assessable patients, I complete response and 20 partial responses were observed yielding a response rate of 34% (95% CI: 22-47). The median response duration was 8.74 months (range 1.6-14). The median time to progression and the median survival were 5.88 months (95% CI: 4.34-8.21) and 18.2 months (95% CI: 10-20.7), respectively. Diarrhoea and peripheral neuropathy were the most frequent and predictable toxicities. These events were reversible, noncumulative and manageable. Grade 3 diarrhoea occurred in only 11% of the patients. No grade 4 gastrointestinal toxicity was reported in the study. The incidence of grade 3/4 (National Cancer Institute Common Toxicity Criteria 2: NCI-CTC 2) peripheral neuropathy was 15%. Haematological toxicity was of mild to moderate intensity with 10% of the patients with Grade 3/4 neutropenia without any episode of complication. The TEGAFOX regimen, a new combination using UFT®/LV and oxaliplatin every 3 weeks is feasible on an outpatient basis. The combination is safe and active and may offer a promising alternative to the intravenous route. Nevertheless this efficacy results should be confirmed by randomized phase III trials. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

23. Lugol chromoendoscopy: might it be useful to improve detection of early dysplastic or neoplastic lesions of the anal canal in high-risk patients?

Author

Antonietti, M., Lecleire, S., Ben Soussan, E., Paillot, B., Di Fiore, F., Lerebours, E., and Ducrott�, P.

Subjects
DYES in medical diagnosis, ENDOSCOPY, TUMORS
Abstract

The article discusses a study that proved the feasibility of Lugol chromoendoscopy in detecting neoplastic lesions of the anal canal in high-risk patients.

Published
2008
Full Text
View/download PDF

28. Raltitrexed (Tomudex®) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)

Author

Popov I, Carrato A, Sobrero A, Vincent M, Kerr D, Labianca R, Bianco AR, El-Serafi M, Bedenne L, Paillot B, Mini E, Sanches E, Welch J, Collette L, Praet M, and Wils J

Abstract

Objectives:PETACC-1 assessed if raltitrexed is non-inferior to 5-fluorouracil and leucovorin for relapse-free survival (RFS) and overall survival (OS) in adjuvant stage III colon cancer.Methods:Non-inferiority required both HR for RFS and OS < 1.25 at 1-sided alpha = 0.05. Patients (1921) were randomised to six cycles of 5-FU/LV (n = 969) or eight cycles of raltitrexed (n = 952). We report the final results in 993 eligible patients who started and completed the allocated treatment (489 5-FU/LV and n = 504 Raltitrexed) of whom respectively 146 and 148 died, respectively.Results:The trial closed prematurely when 17 (1.9%) raltitrexed-related deaths were reported. Haematological and gastrointestinal toxicities were more frequent with 5-FU/LV, liver toxicities with raltitrexed. Raltitrexed was stopped for toxicity in 13.2% and 5-FU/LV in 8.5%. Sixty-day mortality was 9% versus 7%. With 4.1 years median follow-up, the HR for RFS was 1.16 (90% CI 0.99-1.37) and that for OS was 1.01 (90% CI 0.84-1.23).Conclusion:The trial failed to demonstrate non-inferiority of raltitrexed. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results